business
Weight loss drug maker sinks 25% after new safety data spooks investors
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects.
- The Danish drugmaker said that while its drug survodutide met its key targets in a late-stage study, 19% of patients dropped out of the study due to gastrointestinal events, compared to 2.9% on placebo.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data on its experimental medicine raised concerns over its potential side effects.
The Danish drugmaker said that while its drug survodutide met its key targets in a late-stage study, 19% of patients dropped out of the study due to gastrointestinal events, compared to 2.9% on placebo.
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
MarketWatch
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug
MarketWatch
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Fortune
Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics
STAT News
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop